click here to return to the Clinical Trials page
Ongoing Clinical Trials
101MS326 |
|
CAMM |
|
CBAF312A2201 (oral pill) |
|
CFTY720D2306 (oral pill) |
|
Drug Research Study for Relapsing/Remitting Multiple Sclerosis |
|
EFC6058 (oral pill) |
|
Estriol Research Study for Relapsing/Remitting Multiple Sclerosis |
|
FTY720 in Relapsing/Remitting MS (Oral Treatment) |
|
Single vs. Double-Dose Copaxone for Relapsing/Remitting MS |
|
Completed Clinical Trials (data being analyzed)
Anti-B Cell Antibody (Rituxan) for Progressive MS |
|
BEYOND Study for Relapsing/Remitting MS |
|
Novantrone in MS |
|
Rebif vs. Copaxone in Relapsing/Remitting MS |
|
Completed Clinical Trials (historical reference)
Antegren Phase II |
|
Antiproliferative Therapy of MS (Paclitaxel) |
|
Aricept Trial in MS |
|
ATM-027 Antibody to T Cell Receptor |
|
Avonex (IFN beta-1a) for First Attack of MS-like Illness (optic neuritis, transverse myelitis, etc.) |
|
Betaseron (IFN beta-1b) for secondary-Progressive MS |
|
Betaseron (Interferon Beta-1b) for Relapsing/Remitting MS |
|
Betaseron: Prevention of Red Spots at Skin Injection Sites |
|
Copaxone (Cop1; Glatiramer acetate) in Primary progressive MS |
|
Copaxone Oral |
|
Cyclosporin for MS |
|
Cytotek (Misoprostol) for MS |
|
Hu23F2G for Acute Exacerbation of MS |
|
(IFN-beta 1b) Betasron Double-Dose (Phase II) |
|
Linomide for Secondary Progressive MS |
|
Natalizumab (Tysabri) Antibody to Adhesion Molecules VLA-4 |
|
(Avandia) PPAR-gamma agonists in Remitting/Relapsing MS |
|
MBP8298-SP-03 |
|
Rebif vs. Avonex Trial |
|
Rebiject Trial in MS |
|
T Cell Receptor Vaccine for MS |
|
Tegison (Vitamin A) for MS |
|
Terbutaline in Chronic Progressive MS |
|
Tizanidine for Spasticity in MS |
|
TNFR-IgG (Lenercept; RO45-2081) for Relapsing/Remitting MS |
|
Zanaflex for Spasticity in MS and Spinal Cord Damage |
|